Intellectual Property and Open Source Technology

The History of IP and Open Source in Zinc Finger Technology

Discovered in 1985, zinc finger proteins have rapidly become a staple of gene therapy innovation. A cascade of research has transformed our understanding of the zinc finger domain from a natural transcription factor to a tool for highly specific genome alteration. As the zinc finger motif was domesticated and fused to DNA cleaving domains, its practical application through targeted gene alteration rose to the forefront of gene therapy research.

Seeking to harness zinc finger potential, researchers and entrepreneurs collaborated to form Sangamo Biosciences in 1995, which emerged as the sole commercial provider of the protein. Today, the Sangamo monopoly raises a variety difficult ethical and economic questions about intellectual property within the zinc finger field, and synthetic biology as a whole. As an open-source alternative to Sangamo’s proprietary system and commercial dominance, Keith Joung and others have published the OPEN system[5] of zinc finger creation. However, while the OPEN system and subsequent improvements are promising for massive zinc finger production, the methods are difficult and time-consuming to implement, and gaps remain in the list of available DNA binding targets.

Harvard iGEM and Human Practices

Where does our project stand in this complex and contentious history?

The objective of our project was to provide an open-source, "reduced-to-practice" method for zinc finger production through the novel application and integration of technologies. This method allows for the rapid creation of custom zinc fingers in a high-volume fashion for targeting novel binding sequences. This, in turn, has enabled us to fill gaps of undiscovered zinc finger binders in the OPEN and CoDA[4] database and other open-source zinc finger databases. Most importantly, our open-source BioBrick materials, detailed protocols, and software tools greatly increase the accessibility of zinc finger technology and help to overcome the prohibitively high price tags of the present market.

We aim to increase the accessibility of our method, which can in turn be applied by others to the generation of novel biological interactions beyond zinc fingers. We wish to share our data and results with the community, highlighting our successes and failures to collectively advance our knowledge of designing novel biological interactions. In addition, we seek to openly address pertinent ethical and legal concerns surrounding the impact of intellectual property in synthetic biology, and to open a dialogue to raise awareness about these issues.

iGEM & IP

The questions raised by this case study are of particular importance for synthetic biology, which has historically placed great emphasis on an open-source nature. iGEM in particular has placed great value on this history. The Registry of Standard Biological parts and the concept of BioBricks are fundamental examples: characterized, standardized parts are available to on the [http://parts.mit.edu registry website] to anyone with Internet access. In fact, IP questions are relevant for many of the technologies developed and used in the competition.

Playing Monopoly

Zinc finger intellectual property is held predominantly by a single commercial research institution, unlike many other areas of research where intellectual property is distributed across a wide variety of interested parties. This institution, [http://www.sangamo.com/index.html Sangamo Biosciences Inc.], is a clinical stage biopharmaceutical company which focuses on zinc finger production for clinical applications. Sangamo has acquired most of the patent rights for the exclusive production and use of zinc finger proteins as DNA-modifying molecules. The result is an imbalance in the legal rights to research zinc fingers and their related medical applications which has notable consequences.

Implications of Monopoly

First, researchers outside of Sangamo may be less motivated to research zinc finger technology because there is less of a foreseeable reward with patent rights blocking any prospect of earning a profit from patenting new technology. Even if there is no profit motive involved, it is impossible to do open source research using purchased zinc fingers, as "scientists who purchase zinc fingers... must sign a license that imposes certain restrictions. To prevent scientists from selling or even sharing ZFNs, there’s a limit to how many animals can be produced [that express the zinc finger nuclease]. Nor can a scientist share anything made using the zinc fingers outside her organization." [3] Additionally, the cost of purchasing a single zinc finger protein from Sigma® Life Science (licencing partner with Sangamo) is prohibitively high - up to $15,000 for a single functioning zinc finger nuclease, which only work as pairs [3] - limiting the possibilities for significant outside research.

Second, Sangamo is able to monopolize the zinc finger market and intellectual capital: this means that they become a powerful, specialized research institution with the ability to potentially achieve progress at a faster pace than multiple individual institutions.

These two effects act in opposite directions from the perspective of making intellectual progress for humanity. Thus we arrive at the central question: Does the Sangamo zinc finger monopoly augment the positive effects of research benefits for humanity and profit for individual researchers? Is the Sangamo research monopoly more beneficial to all involved parties?

Opening the Field

The economic consequences of monopoly have, of course, been posed by some as a clear negative consequence of the Sangamo phenomenon. The lack of transparency in the field ultimately inhibits outside research while promoting Sangamo’s internal research. In a single-actor monopoly, standard economic theory predicts that the rational market actor will sell at the profit-maximizing price. This price, however, does not necessarily maximize social benefit especially since monopolistic trade results in deadweight loss [1]. In other words, this means that the collective world production of societal benefits - such as medical treatments - potentially decreases in order to maximize profit for Sangamo.

One article "argues that a monopoly isn’t innate to the IP of a single company; the brute force of numbers and sheer innovation can break a monopoly." [6] According to Richard Jefferson, open-source proponent, “There are more smart zinc finger and recombinant scientists in the world than Sangamo can ever hope to have inside their company.”[6] In his opinion, "the first task is to produce a detailed, publicly available 'patent landscape' that describes the field. The second is to exploit the weaknesses through a collaborative open source project that invents beyond the monopoly. New technologies are then made freely available." [6] This is the principle that OPEN, CODA, and Harvard iGEM have embraced: by working together, open-source projects can change a monopoly-dominated field of research.

Another problem with the monopolistic model arises when the company fails: when it fails to make scientific progress, and the whole field suffers. Recently, Sangamo Biosciences’ lead drug candidate has flunked its biggest test yet in clinical trials, and the company said this morning [October 3 2011] that it’s time to move on to other programs.[Sangamo] said today that SB-509 failed in a study of 170 patients that randomly assigned patients with diabetic neuropathy to a new drug or a placebo." [8] If concerns of IP violation discouraged other researchers from working on comparable zinc finger-based treatments for that disease, there is now nothing to show for years of work, and the disease remains untreatable from a gene therapy approach.

Two Sides to Every Story: Benefits of IP

However, others have argued that concentrating intellectual property in a single company has actually promoted innovation and progress in the field [2].

Monetary incentive to conduct research is undoubtedly a key driving force for scientific progress. What scientist or institution would invest in research without at least a chance of returning profit? Lack of protection of intellectual property rights would diminish the sense of security and equality that the U.S. patent system currently provides. In fact the U.S. patent system was first instated to encourage openness of knowledge. Sangamo's large patent share gives the impression that intellectual property rights block future research incentive. In fact without intellectual property rights zinc finger research (and Sangamo) may not even exist today.

By bringing leaders in the field together, Sangamo might allow zinc finger researchers to be more productive through close collaboration than they otherwise would have been working individually. Furthermore, specialization in zinc finger technology minimizes costs of production that individual researchers would otherwise face. From the perspective of consumers purchasing zinc fingers, valuable time and negotiation costs may be saved by working with one company rather than many.

Conclusion: Striking a Balance

The ultimate goal of both Sangamo and other researchers is to make progress in scientific innovation while gaining profit from intellectual property. Naturally both Sangamo and other science researchers will tend to maximize personal profit; however, we suggest that the optimal scenario would maximize both scientific progress and the collective profit gained by each research actor.

This optimal point can be achieved only by a proper balance between intellectual property right regulation and open source technology; therefore we propose that there be an investigation into the current status of the zinc finger intellectual market with respect to the social and private profit-maximizing values. Currently the market lies heavily in favor of maximizing the private profits for Sangamo and the chance that this is the overall profit-maximizing equilibrium is therefore lessened. Only by properly informing the scientific community of the implications of imbalance between intellectual property rights and open source technology can we hope to achieve the most efficient research conditions for the future of synthetic biology research.

One way to do this would be to follow the model of the European Union. In most European countries, patent laws "include a 'research exception' which permits use of a patented invention for experimental purposes without infringing the rights of the holder. Additionally, there are further exceptions such as those in respect of private and non-commercial use." [7] In the United Kingdom, specifically, "those acts which do not constitute an infringement are set out in Section 60(5) of the Patents Act 1977."[7] How can the United States remain competitive in the long-term with countries who allow for academic research without fear of infringement - and have done so for the past 40 years?

A research exception could provide the needed balance between IP and research: companies could maintain their profitability, while scientists could use the best methods and ideas in their academic research, without fear of litigation.

For more information on Harvard iGEM's Human Practices activism,visit http://harvardigem.org/

References

1. Mankiw, G. (2012). Principles of Economics. New York: South-Western Cengage Learning.

2. Chandrasekharan, S., Kumar, S., Valley, C., & Rai, A. (2009). Proprietary science, open science and the role of patent disclosure: the case of zinc-finger proteins. Nature Biotechnology, 140-144. [http://www.nature.com/nbt/journal/v27/n2/full/nbt0209-140.html#B36]

3. Gorman, R. (2010, Fall). Zinc Fingers: Entry Fee. Proto: Massachusetts General Hospital, Dispatches from the Frontiers of Medicine, pp. 35-39. [http://protomag.com/assets/zinc-fingers-entry-fee]

4. Jeffry D Sander, Elizabeth J Dahlborg, Mathew J Goodwin, Lindsay Cade, Feng Zhang, Daniel Cifuentes, Shaun J Curtin, Jessica S Blackburn, Stacey Thibodeau-Beganny, Yiping Qi, Christopher J Pierick, Ellen Hoffman, Morgan L Maeder, Cyd Khayter, Deepak Reyon, Drena Dobbs, David M Langenau, Robert M Stupar, Antonio J Giraldez, Daniel F Voytas, Randall T Peterson,Jing-Ruey J Yeh, J Keith Joung. Selection-free zinc-finger-nuclease engineering by context-dependent assembly (CoDA)(2011). Nature Methods 8, 67–69. [http://www.nature.com/nmeth/journal/v8/n1/full/nmeth.1542.html]

5. Morgan L. Maeder, Stacey Thibodeau-Beganny, Anna Osiak, David A. Wright, Reshma M. Anthony, Magdalena Eichtinger, Tao Jiang, Jonathan E. Foley, Ronnie J. Winfrey, Jeffrey A. Townsend, Erica Unger-Wallace, Jeffry D. Sander, Felix Müller-Lerch, Fengli Fu, Joseph Pearlberg, Carl Göbel, Justin P. Dassie, Shondra M. Pruett-Miller, Matthew H. Porteus, Dennis C. Sgroi, A. John Iafrate, Drena Dobbs, Paul B. McCray Jr., Toni Cathomen, Daniel F. Voytas, J. Keith Joung. Rapid “Open-Source” Engineering of Customized Zinc-Finger Nucleases for Highly Efficient Gene Modification (2008). Molecular Cell Volume 31, Issue 2, 25 July 2008, Pages 294-301.[http://www.sciencedirect.com/science/article/pii/S1097276508004619]

6. Christopher Thomas Scott. The zinc finger nuclease monopoly. Nature Biotechnology Vol23 Num8, 2005.[http://www.cambia.org/daisy/cambia/1186/version/default/part/AttachmentData/data/'The_zinc_finger_nuclease_monopoly'.pdf]

7. UK Intellectual Property Office. The Patent Research Exception: A Consultation. 2008.[http://www.ipo.gov.uk/consult-patresearch.pdf]

8. Luke Timmerman. Sangamo Fails Diabetic Neuropathy Study, Falls Back on HIV, Other Programs. Xconomy, 10/3/11. [http://www.xconomy.com/san-francisco/2011/10/03/sangamo-fails-diabetic-neuropathy-study-falls-back-on-hiv-other-programs/]